NMN vs NR for NAD+ Boosting: What 2024-2025 Research Actually Shows
A comparative review of NMN and NR supplements weighs tissue targeting, clinical evidence, and top-rated products for NAD+ optimization.
20 articles
A comparative review of NMN and NR supplements weighs tissue targeting, clinical evidence, and top-rated products for NAD+ optimization.
Expert reviews confirm NR and NMN raise blood NAD+, but longevity proof remains elusive and product quality varies widely.
A rigorous product review reveals major quality gaps in NAD+ supplements and what dosing evidence actually supports.
A candid breakdown of top NAD+ booster brands reveals strong biomarker data but slim evidence for real longevity outcomes.
Expert reviews compare NMN and NR head-to-head. NMN edges out for muscle and sleep benefits; NR leads for neuroprotection.
A 2026 comparative review of leading NAD+ supplements reveals NR has stronger human data, while NMN marketing often outpaces clinical proof.
Both NMN and NR raise NAD+ levels in humans, but clinical proof of anti-aging benefits is still lacking โ and product quality varies widely.
Expert reviews compare leading NMN and NR supplements on clinical evidence, purity, and value โ with key caveats on what the science can and cannot yet prove.
New expert reviews compare NMN and NR head-to-head, ranking top products by purity, absorption, and clinical evidence.
A head-to-head comparison of NMN and NR supplements reveals distinct benefit profiles โ and major quality gaps across popular brands.
Expert reviews compare NMN and NR on human trial data, bioavailability, and top-ranked brands for 2026.
Expert reviews compare leading senolytic and NAD+ supplement brands on ingredients, evidence quality, and value.
A Cochrane meta-analysis of 8 RCTs finds most pharmacological treatments fail to improve ataxia scores, though upper limb dexterity may benefit.
A Cochrane meta-analysis of 11 RCTs finds very low-certainty evidence that liver support systems neither reduce mortality nor improve key outcomes in ALF.
A Cochrane meta-analysis of 17 RCTs finds amyloid-targeting antibodies offer minimal cognitive gains while significantly raising ARIA risk.
A landmark review reveals how sustained glucocorticoid exposure drives aging biology โ and what can be done about it.
A new Cell Metabolism review from NIH identifies how ECM stiffening, poor blood flow, and mitochondrial failure lock tissues into accelerating decline.
Longevity experts endorse CGMs for metabolic optimization, but RCT evidence in non-diabetics is still thin.
A landmark review argues neurodegeneration is driven by interacting misfolded proteins, not single culprits โ reshaping diagnosis and treatment.
Longevity experts endorse short CGM trials for non-diabetics, but RCT evidence remains thin. Here's what the data actually shows.